Search Omemee Pigeon eFlyer
Custom Search

Tuesday, May 22, 2012

Health Canada Issues Medicine Cancer Risk ALERT! -REVLIMID®

Health Canada Issued the Following Cancer Risk Warning concerning REVLIMID® aka lenalidomide capsules. REVLIMID® is used to treat some patients who require blood transfusions for anemia, as well as people with multiple myeloma - a cancer of plasma cells.

image Health Canada Banner


Subject: Association of REVLIMID® (lenalidomide) with risk of second cancers

Celgene Inc., in consultation with Health Canada, has informed Canadian healthcare providers of important information related to the safety of REVLIMID® (lenalidomide) capsules.

Health Canada has authorized REVLIMID® for the treatment of patients with a condition called deletion 5q myelodysplastic syndrome (del 5q MDS) who require blood transfusions for anemia (low red blood cell counts). REVLIMID® is also authorized when used with dexamethasone to treat patients with multiple myeloma who have already had another treatment. Multiple myeloma is a cancer of plasma cells.

Celgene Inc. has worked with Health Canada to update the REVLIMID® Product Monograph with the following safety information:

• Second cancers such as skin cancers or other invasive solid tumors have been reported in a small number of patients with multiple myeloma.
• These cases have been reported in patients while taking REVLIMID® or after treatment with REVLIMID® is completed.
• Patients should talk to their healthcare professionals if they have any concerns about their own increased risk of having other cancers.

Read full details on the Health Canada website at: Health Canada Medical Advisories

No comments:

Post a Comment

TERMS OF USE

Those who post comments are accountable for the opinions they express, and the accuracy of the information they furnish. While we encourage writers to utilize this service on our site, we also strongly suggest they treat it as public forum where good taste counts. We reserve the right to decline for approval objectionable material from this site.

Writers that include profanity or personal attacks or other inappropriate comments - such as racist language, threats or comments unrelated to the story - will not be approved. Also, entries that are unsigned or signatures by someone other than the actual writer will not be approved.

While writers can still post anonymously, we strongly suggest that they do not do so.

Opinions, guidance and other information expressed in Omemee Pigeon eFlyer comments and by contributors to the Omemee Pigeon eFlyer, represent the individuals'; own views and are not necessarily those of the Omemee Pigeon eFlyer. The Omemee Pigeon eFlyer furnishes this type of forum and does not endorse and is not accountable for statements or advice from anyone other than an designated Omemee Pigeon eFlyer spokesperson.

F.A.Q.

(Frequently Asked Questions) Choose your favourite and send a letter to the editor. 1. Why isn't this paper being run on a "dot com"? 2. Who is running this paper? 3. Why do you have Google ads on here? 4. Where can I get a print copy of this paper? 5. How can I help make this paper even better? 6.I'd like to buy you a coffee.Where can I send a donation? Thanks! Every bit helps!

Who Reads Omemee Pigeon eFlyer?

You do! Most readers are from our direct area,but people the world over do read Omemee Pigeon eFlyer. We currently have over 2,000 accounts getting our headlines,and almost 100 daily email subscribers. Not bad for a little eZine just starting out. We are especially excited about the writers joining in this project!

Come Tweet Us!

Related Posts Plugin for WordPress, Blogger... Google+